Group 1 - Harbin Air Conditioning plans to transfer 40% equity of its subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. The subsidiary reported a net profit of -16.0963 million yuan for 2024, which is 218.83% of the previous year's net profit absolute value [1] - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 45% to 65% [1][2] - Gansu Energy anticipates a net profit of 1.55 billion to 1.6 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 11.86% to 15.47% [2][3] Group 2 - Dongfang Tower forecasts a net profit of 750 million to 900 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 60.83% to 93% [4] - Meili Eco announced that its subsidiary won a bid for an EPC project worth 2.375 billion yuan [6] - Bohai Chemical's wholly-owned subsidiary will undergo routine maintenance for its 600,000 tons/year PDH unit, expected to last about 30 days [8] Group 3 - Qin Port Co. reported a total throughput of 317.02 million tons for the first nine months of 2025, a year-on-year increase of 5.56% [10] - Jianglong Shipbuilding won a bid for a 72.99 million yuan fishery enforcement vessel project, accounting for 4.22% of its 2024 audited revenue [11] - Longyuan Technology expects a net profit of 35 million to 40 million yuan for the first three quarters of 2025, representing a year-on-year increase of 50.11% to 71.55% [12] Group 4 - Naipu Mining anticipates a net profit of 61 million to 66 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 45.16% to 49.32% [14] - Jinggong Steel Structure reported a cumulative contract amount of 17.98 billion yuan for the first nine months of 2025, a year-on-year increase of 4.8% [15][16] - Shenzhen Gas reported a net profit of 918 million yuan for the first three quarters of 2025, a year-on-year decrease of 13.08% [17] Group 5 - Yabao Pharmaceutical's subsidiary received a drug registration certificate for a new diabetes medication [18] - Shaanxi Coal's coal production in September was 14.56 million tons, a year-on-year increase of 5.34% [20] - Sifang New Materials reported a 15.94% year-on-year decline in concrete production for the first three quarters [22] Group 6 - Nanjing Foods reported a consolidated revenue of 276 million yuan in September, a slight increase of 0.0016% year-on-year [23] - Pulaike received a new veterinary drug registration certificate for a flea and tick treatment [24] - Zhucheng Technology received a cash dividend of 15 million yuan from its subsidiary [25] Group 7 - David Medical's subsidiary received a medical device registration certificate for a portable electronic endoscope image processor [26] - Zhongtong Bus reported a 36.88% year-on-year increase in sales in September, totaling 1,106 units [27] - Xiantan Co. reported a 11.95% year-on-year increase in chicken sales revenue in September [28] Group 8 - Bojun Technology expects a net profit of 552 million to 662 million yuan for the first three quarters of 2025, a year-on-year increase of 50% to 80% [30] - Haishi Pharmaceutical's innovative pain relief drug clinical trial application has been accepted [31] - Lingxiao Pump Industry used 80 million yuan of idle funds to purchase financial products [32] Group 9 - Qiangda Circuit's subsidiary completed business registration changes to expand its operational scope [33] - *ST Tianyu's controlling shareholder applied for bankruptcy liquidation due to severe financial difficulties [34] - Baolidi's shareholder plans to reduce holdings by up to 1 million shares [36] Group 10 - Zijin Mining completed the acquisition of Kazakhstan's Raygorodok gold mine, controlling 100% of its rights [44] - Zhonggang Luoyang's indirect controlling shareholder completed a capital increase, raising registered capital from approximately 26.666 billion yuan to 44.824 billion yuan [46] - Jinyu Jidong's director resigned due to work adjustments [47]

Policy Developments - The "Regulations on the Management of Clinical Research and Clinical Translation Applications of Biomedical New Technologies" were officially published, emphasizing the balance between innovation and safety in the biomedical sector [2] - The National Healthcare Security Administration has issued a draft for "Basic Medical Insurance Registration Service Specifications," mandating that registration for individuals or units must not exceed five working days [3] Industry News - The National Healthcare Security Administration is conducting a special investigation into "dual pricing" practices at designated retail pharmacies, which discriminate between insured and uninsured patients [4] - Keren Biotechnology's TROP2 ADC has received approval for second-line treatment of EGFR mutation NSCLC, marking a significant advancement for the company's core product [6] - Beijing Norsland Biotechnology Co., Ltd. plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and raise funds for long-term development [8] - The National Medical Products Administration has reclassified Dangshen Granules and Regulating Menstrual Blood Capsules from prescription to over-the-counter drugs [10] - KingMed Diagnostics, Tencent, and Guangzhou Medical University First Affiliated Hospital announced a collaboration to develop a multimodal model for pathological genetics using AI [11] Company Updates - Kangtai Medical received a warning letter from the FDA regarding non-compliance with medical device quality system regulations, which could prevent its products from entering the U.S. market until issues are resolved [14] - Warner Pharmaceuticals has voluntarily withdrawn its drug registration application for Arolol Hydrochloride Tablets, which will not significantly impact the company's current or future operations [15]

Core Viewpoint - Hunan Warner Pharmaceutical Co., Ltd. has voluntarily withdrawn its drug registration application for Arolol Hydrochloride Tablets, which is primarily used for treating primary hypertension, angina, tachyarrhythmia, and essential tremor [1] Group 1: Company Actions - The company submitted the marketing authorization application for Arolol Hydrochloride Tablets to the National Medical Products Administration in April 2024 and received acceptance [1] - After careful consideration and alignment with its research and development strategy, the company decided to withdraw the drug registration application [1] Group 2: Impact on Operations - The voluntary withdrawal of the drug registration application will not have a significant impact on the company's current and future production operations and performance [1]

湖南华纳大药厂股份有限公司 自愿披露关于撤回药品注册申请的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）收到国家药品监督管理局核准签发的《药品注 册申请终止通知书》，同意公司撤回盐酸阿罗洛尔片的注册申请。现将相关情况公告如下： ■ 证券代码：688799 证券简称：华纳药厂 公告编号：2025-079 盐酸阿罗洛尔片主要用于治疗原发性高血压（轻度-中度）、心绞痛、心动过速性心律失常、原发性震 颤。 公司于2024年4月向国家药品监督管理局递交该产品的上市许可申请并获得受理。经审慎研究，结合研 发策略，公司决定主动撤回本次药品注册申请。 该药品注册申请的主动撤回并终止不会对公司当期及未来生产经营与业绩产生重大影响。敬请广大投资 者注意投资风险。 特此公告。 湖南华纳大药厂股份有限公司董事会 2025年10月13日 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has received approval from the National Medical Products Administration to withdraw its drug registration application for Arolol Hydrochloride Tablets [1] Group 1 - The drug Arolol Hydrochloride Tablets is primarily used for the treatment of essential hypertension (mild to moderate), angina pectoris, tachyarrhythmia, and essential tremor [1]

Core Viewpoint - Hunan Warner Pharmaceutical Co., Ltd. has received a notice from the National Medical Products Administration regarding the termination of its drug registration application for Arolol Hydrochloride Tablets, which are primarily used for treating primary hypertension [1] Group 1 - The drug in question is classified as a Class 4 chemical drug with the acceptance number CYHS2401127 [1] - The company submitted the marketing authorization application in 2024 but has decided to withdraw it after careful consideration and alignment with its research and development strategy [1]

成都苑东生物制药股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局（以下简称"国家 药监局"）核准签发的《药品注册证书》，现将相关情况公告如下： 一、药品基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 药品名称：盐酸阿罗洛尔片 剂型：片剂 规格：10mg 注册分类：化学药品4类 药品有效期：18个月 上市许可持有人：成都苑东生物制药股份有限公司 生产企业：成都苑东生物制药股份有限公司 药品注册标准编号：YBH22152025 受理号：CYHS2402067 二、药品的其他相关情况 盐酸阿罗洛尔片主要活性成份为盐酸阿罗洛尔，主要适应症为原发性高血压（轻度-中度）、心绞痛、 心动过速性心律失常、原发性震颤。 盐酸阿罗洛尔片由日本住友公司开发，最早于1985年11月在日本获批上市，于1995年8月在进口中国。 盐酸阿罗洛尔片属于《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》乙类品种。国家 药监局官网显示，国内已有石家庄格瑞药业、北京鑫诺康桥、山 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688513 证券简称：苑东生物 公告编号：2025-063 成都苑东生物制药股份有限公司 关于自愿披露盐酸阿罗洛尔片获得药品注册证书的公告 剂型：片剂 规格：10mg 注册分类：化学药品4类 药品有效期：18个月 上市许可持有人：成都苑东生物制药股份有限公司 生产企业：成都苑东生物制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局（以下简称"国家 药监局"）核准签发的《药品注册证书》，现将相关情况公告如下： 一、药品基本情况 药品名称：盐酸阿罗洛尔片 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求， 批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附执行。药品生产企业应当符 合药品生产质量管理规范要求方可生产销售。 二、药品的其他相关情况 盐酸阿罗洛尔片主要活性成份为盐酸阿罗洛尔，主要适应症为原发性高血压（轻度-中 ...

Core Points - The company, Yuandong Biological, announced the receipt of a drug registration certificate from the National Medical Products Administration for its product, Arolol Hydrochloride Tablets [2] Group 1 - The drug name approved is Arolol Hydrochloride Tablets [2] - The approval was granted by the National Medical Products Administration [2]

Core Viewpoint - Yuan Dong Biotech (688513.SH) has received the Drug Registration Certificate from the National Medical Products Administration for its product, Arolol Hydrochloride Tablets, which is indicated for primary hypertension (mild to moderate), angina pectoris, tachyarrhythmias, and essential tremor [1] Group 1 - The active ingredient of the newly approved drug is Arolol Hydrochloride [1] - The drug is primarily indicated for treating mild to moderate primary hypertension [1] - Additional indications include angina pectoris, tachyarrhythmias, and essential tremor [1]